Motif Bio Poised For Filings As Iclaprim Succeeds Again In Phase III

 
• By Alexandra Shimmings

Positive data from a second Phase III trial sets up Motif Bio for an NDA filing by the end of the year for novel antibiotic iclaprim – but success for the product has been a long time coming.

Leopard
Motif Bio Getting Ready to pounce on $2bn+ market • Source: Shutterstock

More from Clinical Trials

More from R&D